Dr. Elyse Joelle McGlumphy, MD

Dr. McGlumphy practices at Delaware Ophthalmology Consultants PA in Wilmington, Delaware.

Dr. McGlumphy's NPI, 1609261460, was assigned on March 30, 2015. Dr. McGlumphy graduated from University of Maryland School of Medicine in 2015. Dr. McGlumphy holds Delaware license C1-0025759.

Dr. McGlumphy's primary practice is Delaware Ophthalmology Consultants PA, at 3509 Silverside Rd, Wilmington, DE 19810 in New Castle County. The practice phone is (302) 479-3937.

Dr. McGlumphy's primary practice is Delaware Ophthalmology Consultants PA in Wilmington, Delaware. Dr. McGlumphy is also affiliated with Select Specialty Hospital - Wilmington. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. McGlumphy to 2 more hospitals, 3 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McGlumphy practices, 4 sites in all. Vendor and product names are available with a free account.

Glaucoma specialist is Dr. McGlumphy's primary specialty in the NPI Registry, under taxonomy code 207WX0009X. Dmand AI has Dr. McGlumphy's licenses on file in 2 states: Delaware and Maryland.

CMS data shows 3,223 Medicare services from Dr. McGlumphy across 15 procedure codes in 2024, for 938 Medicare patients. Medicare paid $223,435 for them.

CMS counts 938 Medicare patients who saw Dr. McGlumphy in 2024. The largest group is 75 to 84, with 400 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 4% are also on Medicaid. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. McGlumphy's median patient age at 74, with 57% women.

In 2024, Dr. McGlumphy wrote 4,390 Medicare Part D claims for 941 patients. 67% of them were for generic drugs. CMS names the drug for 4,271 of them, across 20 drugs with 11 or more claims each, at $390,478 in total drug cost. In 2023, CMS named 4,454 claims across 21 drugs.

Dr. McGlumphy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 181 procedures of cataract surgery by Dr. McGlumphy, more than 82% of the clinicians it reports for that procedure.

Dmand AI links 16 papers to Dr. McGlumphy, published from 2010 to 2024. 2023 was the busiest year, with 3. The most frequent topics are Fuchs' Endothelial Dystrophy, Glaucoma and Endothelium, Corneal. Dr. McGlumphy has published most often in Ophthalmol Glaucoma. Dr. McGlumphy's most frequent co-authors are John D. Gottsch, MD, Allen Omid Eghrari, MD and Benjamin William Iliff, MD.

CMS Open Payments shows 43 general payments to Dr. McGlumphy from 10 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 60% of the total. W. L. Gore & Associates, Inc. paid the most, $660.

Dr. McGlumphy graduated from University of Maryland School of Medicine in 2015.